Death rates from ovarian cancer have fallen by 20 per cent over last decade

November 20, 2012
Death rates from ovarian cancer have fallen by 20 per cent over last decade

The rates of women dying from ovarian cancer in England have fallen from 11.2 women in every 100,000 (3,820 cases) in 2001 to 8.8 per 100,000 (3,453 cases) in 2010 – a drop of around 20 per cent, according to a new report by the National Cancer Intelligence Network published today.

And the most notable drop in deaths over the last 10 years has been among women aged 40-69 years old.

The report also showed that survival for ovarian cancer has increased since the mid-1980s – women surviving their disease for at least a year has risen from 57 to 73 per cent and five year survival has increased from 33 to 44 per cent.

But the report found the chance of surviving the disease varies widely between ages, becoming increasingly worse with age, even after adjusting for the higher background mortality in the older population generally. For women aged 15-39 diagnosed with ovarian cancer, 84 per cent survived their disease for at least five years compared with just 14 per cent of those aged over 85 years at diagnosis.

In 2009 almost half of women diagnosed with ovarian cancer were in their 60s or 70s – and over 80 per cent of deaths were in women aged 60 or over.

Dr Andy Nordin, gynaecological at East Kent Hospitals University NHS Foundation Trust and study author, said: "Our new report is very encouraging and shows a fall in the rates of women dying from ovarian cancer – a type of cancer that has always been notoriously hard to treat. This is because ovarian cancer is a group of different disease types, which is difficult to diagnose and commonly presents as advanced disease. This drop in deaths may reflect improvements in detecting and treating the disease, such as improvements in scanning, surgery and treatments.  Additionally, over the past decade, ovarian throughout the UK have experienced better management due to organisation of ovarian in specialist gynaecological cancer centres, planning of care by teams of cancer experts and specialist surgery by specially trained and accredited gynaecological oncologists."

The report also highlights that the incidence rates for developing the disease have remained fairly stable since the late 1980s although they have dropped slightly in the last few years.

Dr Nordin, added: "We know the risk of developing some types of ovarian cancer may be related to the number of times a women ovulates during her lifetime. And anytime that she stops ovulating such as during pregnancy and breast feeding, early menopause and taking the contraceptive pill all help to protect against the disease developing.  The fall in incidence could therefore partially reflect the widespread use of hormonal contraceptives since the '60s."

Chris Carrigan, head of the National Cancer Intelligence Network (NCIN), said: "As  ovarian cancer can be very hard to diagnose and treat this report was important to help us learn as much as we can about the numbers of women who develop the disease, how many survive and how many die."

is the fifth most common cancer in in the UK with around 7,000 cases diagnosed each year.

Explore further: Pill and pregnancy have biggest effects on ovarian cancer risk

More information: Overview of Ovarian Cancer in England: Incidence, Mortality and Survival, November 2012, Trent Cancer Registry National Cancer Intelligence Network (NCIN).

Related Stories

Pill and pregnancy have biggest effects on ovarian cancer risk

October 26, 2011
(Medical Xpress) -- Taking the Pill for 10 years can reduce the risk of ovarian cancer by almost half (45 per cent), new research part-funded by Cancer Research UK shows today.

Differences in treatment for advanced ovarian cancer could explain why UK survival lags behind other countries

October 4, 2012
The main reason women are less likely to survive ovarian cancer in the UK than in other comparable countries appears to be due to very low survival in those with more advanced stages of the disease, shows new research published ...

Routine screening for ovarian cancer a failure: study

September 11, 2012
Routine screening for ovarian cancer is ineffective and at times can do more harm than good, a panel of cancer specialists has concluded.

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.